Lung Cancer
Volume 75, Issue 2 , Pages 261-267 , February 2012

Raltitrexed plus cisplatin is cost-effective compared with pemetrexed plus cisplatin in patients with malignant pleural mesothelioma

  • Beth Woods

      Affiliations

    • Oxford Outcomes, Oxford, UK
    • Corresponding Author InformationCorresponding author at: Oxford Outcomes, Seacourt Tower, West Way, Botley, Oxford, OX2 0JJ, UK. Tel.: +44 1865 324 930; fax: +44 01865 324 931.
    • ,
  • Noman Paracha

      Affiliations

    • Oxford Outcomes, Oxford, UK
    • ,
  • David A. Scott

      Affiliations

    • Oxford Outcomes, Oxford, UK
    • ,
  • Nicholas Thatcher

      Affiliations

    • Christie Hospital NHS Trust, Manchester, UK
    • Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester, M20 4BX.

Received 20 April 2011 ,Revised 8 July 2011 ,Accepted 16 July 2011.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0169-5002(11)00385-0

doi: 10.1016/j.lungcan.2011.07.011

Lung Cancer
Volume 75, Issue 2 , Pages 261-267 , February 2012

Article Tools

* Image Usage & Resolution